LEIDEN, NETHERLANDS--(Marketwire - November 13, 2007) -
Total revenue and other operating income increased by 115% to EUR 62.6 million in the third quarter compared to the same quarter last year, largely driven by increased sales of Quinvaxem™ and Inflexal® V.
